Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends That Will Shape the Next Decade: Insights from Glaxosmithkline Introduces Trelegy Ellipta A Revolutionary Single-Inhaler Triple Treatment For Chronic Obstructive Pulmonary Disease (COPD)

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size By 2025?
The market size for treatments of chronic obstructive pulmonary disease (COPD) has seen significant growth in recent years. The market, valued at $20.84 billion in 2024, is projected to increase to $21.94 billion in 2025, at a compound annual growth rate (CAGR) of 5.3%. Factors contributing to this surge during the historic period include a rise in tobacco consumption and smoking, advancements in inhalation therapies, increase in public awareness and early diagnosis initiatives, government policies promoting respiratory health, and ongoing research and development in pulmonology.

How Big Is the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size Expected to Grow by 2029?
The market size for the treatment of chronic obstructive pulmonary disease (COPD) is predicted to experience substantial growth in the forthcoming years, reaching ""$27.74 billion by 2029 with an estimated compound annual growth rate (CAGR) of 6.0%. Factors contributing to the growth in this forecast period include progression in personalized medicine and biomarker research, the advent of biologic therapies and targeted interventions, concerns about air quality and environmental influences, worldwide smoking cessation efforts, and partnership in drug invention. Notable trends for the projected period encompass digital health approaches for managing COPD, the proliferation of biologic therapies, the rise of personalized medicine, the utilization of combination therapies and inhalers, the emphasis on early detection and intervention, alongside pulmonary rehabilitation programs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Which Key Market Drivers Powering Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Expansion and Growth?
The escalating incidence of lung disease is anticipated to drive the expansion of the chronic obstructive pulmonary disease (COPD) treatment market. Lung disease impedes proper functioning of the lungs owing to disorders that affect them. Asthma, COPD, and lung cancer are amongst the most prevalent lung diseases. The primary purpose of Chronic obstructive pulmonary disease (COPD) treatment includes lung disease treatment, slowing the rate of disease progression, symptom management, and preventing further damage to the lungs with the use of inhalers and medication. As per the global initiative for Chronic obstructive lung disease (GOLD), a non-profit organization based in the US, in September 2022, annually, around 3.2 million people die due to the chronic obstructive pulmonary disease (COPD), affecting nearly 200 million people worldwide. Additionally, in 2022, 262 million people globally suffered from asthma. These figures are predicted to increase in the future. Furthermore, as per the US-based non-profit organization, LUNGevity Foundation, around 127,000 Americans will die each year due to lung cancer in the US by 2023. Therefore, the escalating incidence of lung disease fuels the expansion of the chronic obstructive pulmonary disease (COPD) treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The trend of product innovation is increasingly shaping the chronic obstructive pulmonary disease (COPD) treatment market. Prominent firms within the chronic obstructive pulmonary disease (COPD) treatment market are striving to solidify their market standing by creating novel products. In an exemplification of this, GlaxoSmithKline plc (GSK), a British pharmaceutical and biotechnology company, unveiled Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol), a first-in-industry single-inhaler triple treatment (SITT) for COPD patients in India in April 2022. Trelegy Ellipta serves as a preventative and treatment maintenance medication targeting the symptoms and signs of COPD in individuals aged 18 and upwards. The medication works comparably to natural corticosteroid hormones, binding to receptors on certain immune cells to dampen immune system activity. Moreover, it aids in reducing lung airway inflammation, facilitating easier breathing.

What Are the Emerging Segments in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The chronic obstructive pulmonary disease (COPD) treatment market covered in this report is segmented -

1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10054&type=smp

Who Are the Global Leaders in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc.

Which are the Top Profitable Regional Markets for the Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024.Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10054

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Contact Us:
The Business Research Company
Europe - +44 7882 955267
Asia: +91 88972 63534
Americas - +1 310-496-7795
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.